Policy Notices

• Additional Guidance on the NIH Policy on the Use of a Single Institutional Review Board for Multi-Site Research
  (NOT-OD-20-058)
  National Institutes of Health
  

• Update of NIH Continuous Submission Policy: Change in Submission Deadlines and End of Recent Substantial Service Option
  (NOT-OD-20-060)
  Center for Scientific Review
  

General Notices

• Notice of a Pre-Application Webinar for NIDCR Institutional Training Program FOAs: T32 (PAR-20-044) and T90/R90 (PAR-20-056)
  (NOT-DE-20-008)
  National Institute of Dental and Craniofacial Research
  

• Notice of Pre-Application Webinars for the Mendelian Genomics Research Centers (RFA-HG-20-007) and Mendelian Genomics Data Coordinating Center (RFA-HG-20-008)
  (NOT-HG-20-018)
  National Human Genome Research Institute
  

• NHLBI Announces http://ags20.od.nih.gov/view/Index.cfmPlan to Fund a Women's Health Initiative Home-Based Exam in the Long Life Study 2 Cohort
  (NOT-HL-20-750)
  National Heart, Lung, and Blood Institute
  

• Notice of NCATS Interest in Receiving Letters Requesting Permission to Submit Applications to Support Annual Microphysiological Systems Scientific Conferences (U13)
  (NOT-TR-20-005)
  National Center for Advancing Translational Sciences
  

• Request for Information (RFI): Interest in data and specimens from the Hemophilia Growth and Development Study (HGDS) for research on HIV-associated comorbidities, coinfections and complications
  (NOT-HL-19-747)
  National Heart, Lung, and Blood Institute
  

Notice of Changes to Funding Opportunities

• Notice to Extend NCCIH PAR-18-663, "Mind and Body Intervention Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Required)"
  (NOT-AT-20-003)
  National Center for Complementary and Integrative Health
  

• Notice to Extend NCCIH's PAR-18-118, "NCCIH Mind and Body Clinical Trial Cooperative Agreement (U01 Clinical Trial Required)"
  (NOT-AT-20-006)
  National Center for Complementary and Integrative Health
  

• Notice of Clarification Relevant to Section IV, Application and Submission Information for PAR-20-046 NIDCR Small Research Grants for Analyses of Existing Genomics Data (R03 Clinical Trial Not Allowed)
  (NOT-DE-20-009)
  National Institute of Dental and Craniofacial Research
  

• Notice of Clarification Relevant to Section IV, Application and Submission Information for PAR-20-045 NIDCR Research Grants for Analyses of Existing Genomics Data (R01 Clinical Trial Not Allowed)
  (NOT-DE-20-010)
  National Institute of Dental and Craniofacial Research
  

• Notice of Change in Expiration Date of PAR-18-643 "NHLBI Clinical Ancillary Studies (R01 Clinical Trial Optional)"
  (NOT-HL-20-747)
  National Heart, Lung, and Blood Institute
  

• Notice of Participation of the NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
  (NOT-MH-20-014)
  National Institute of Mental Health
  

• Notice to Extend RFA-MH-20-310 BRAIN Initiative: Non-Invasive Neuromodulation - New Tools and Techniques for Spatiotemporal Precision (R01 Clinical Trial Optional)
  (NOT-MH-20-030)
  National Institute of Mental Health
  

Funding Opportunities

• Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)
  (PAR-20-092)
  National Institute on Drug Abuse
  Application Receipt Date(s): Applications will be accepted on a rolling basis, beginning on February 24 , 2020 .
  
  

• Harmonization of Alzheimers Disease and Related Dementias (AD/ADRD) Genetic, Epidemiologic, and Clinical Data to Enhance Therapeutic Target Discovery (U24 Clinical Trial Not Allowed)
  (PAR-20-099)
  National Institute on Aging
  Application Receipt Date(s): Standard dates apply. The first standard due date for this FOA is May 25, 2020.
  
  

• Genomic Community Resources (U24 Clinical Trial Not Allowed)
  (PAR-20-100)
  National Human Genome Research Institute
  National Cancer Institute
  Application Receipt Date(s): May 25, 2023
  
  

• Genomic Expert Curation Panels (U24 Clinical Trial Not Allowed)
  (PAR-20-101)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Cancer Institute
  National Eye Institute
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): May 27, 2020, May 27, 2021, May 27, 2022,
  
  

• HEAL Initiative: Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) (UG3/UH3, Clinical Trials Optional)
  (RFA-AT-20-004)
  National Center for Complementary and Integrative Health
  National Center for Advancing Translational Sciences
  National Cancer Institute
  National Institute on Aging
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Dental and Craniofacial Research
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): March 30, 2020, No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
  (RFA-CA-20-007)
  National Cancer Institute
  Application Receipt Date(s): June 9, 2020; November 18, 2020
  
  

• Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
  (RFA-CA-20-008)
  National Cancer Institute
  Application Receipt Date(s): June 9, 2020; November 18, 2020
  
  

• Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
  (RFA-CA-20-009)
  National Cancer Institute
  Application Receipt Date(s): June 09, 2020; November 18, 2020
  
  

• Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
  (RFA-CA-20-010)
  National Cancer Institute
  Application Receipt Date(s): June 09, 2020; November 18, 2020
  
  

• Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 Clinical Trials Optional)
  (RFA-CA-20-011)
  National Cancer Institute
  Application Receipt Date(s): June 9, 2020; November 18, 2020
  
  

• Revision Applications to Support the Application of Informatics Technology for Cancer Research (U01 Clinical Trials Optional)
  (RFA-CA-20-012)
  National Cancer Institute
  Application Receipt Date(s): June 09, 2020; November 18, 2020
  
  

• Revision Applications to Support the Application of Informatics Technology for Cancer Research (U24 Clinical Trial Optional)
  (RFA-CA-20-013)
  National Cancer Institute
  Application Receipt Date(s): June 09 2020; November 18, 2020
  
  

• HIV/AIDS and the Tumor Niche (U54 Clinical Trial Not Allowed)
  (RFA-CA-20-016)
  National Cancer Institute
  Application Receipt Date(s): July 15, 2020
  
  

• Urology Centers Program Interactions Core (U24 Clinical Trial Not Allowed)
  (RFA-DK-19-034)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 31, 2020 No late applications will be accepted for this Funding Opportunity Announcement
  
  

• Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Clinical Centers (Collaborative U01 Clinical Trial Required)
  (RFA-DK-20-501)
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Cancer Institute
  National Institute on Aging
  Application Receipt Date(s): April 22, 2020
  
  

• Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Biostatistics Research Center (BRC) (Collaborative U01 Clinical Trial Required)
  (RFA-DK-20-502)
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Cancer Institute
  National Institute on Aging
  Application Receipt Date(s): April 22, 2020
  
  

• Advancing Conformance with the Voluntary National Retail Food Regulatory Program Standards (VNRFRPS) (U18) Clinical Trials Not Allowed
  (RFA-FD-20-012)
  Food and Drug Administration
  Application Receipt Date(s): March 27, 2020 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  
  

• Building an Integrated Laboratory System to Advance the Safety of Human and Animal Food (U18) Clinical Trial Not Allowed
  (RFA-FD-20-013)
  Food and Drug Administration
  Application Receipt Date(s): March 23, 2020 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  
  

• Conduct Studies to Establish More Targeted Durations of Use for Certain Approved Antimicrobial New Animal Drugs in Food Animals (U01) Clinical Trials Optional
  (RFA-FD-20-025)
  Food and Drug Administration
  Application Receipt Date(s): May 1, 2020, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  
  

• HEAL Initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development (R61/R33 - Clinical Trial Not Allowed)
  (RFA-HL-20-031)
  National Heart, Lung, and Blood Institute
  National Institute on Drug Abuse
  Application Receipt Date(s): March 24, 2020 No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• HEAL Initiative: Pain Management Effectiveness Research Network: Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
  (RFA-NS-20-028)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute on Minority Health and Health Disparities
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): March 24, 2020